The transaction, managed by exclusive placement agent H.C. Wainwright & Co., involved the sale of 4,081,633 shares of common stock—or pre-funded warrants—priced at $0.735 each. The accompanying warrants are structured to trigger upon shareholder approval of the issuance. The Series A warrants remain valid for five years, while the short-term Series B warrants expire in eighteen months.

FibroBiologics intends to direct the net proceeds toward working capital and general corporate operations. As a clinical-stage entity, the company currently maintains a portfolio of over 270 patents focusing on fibroblast-based treatments for conditions ranging from multiple sclerosis to disc degeneration. The securities were sold under Section 4(a)(2) of the Securities Act, and the firm has committed to filing a resale registration statement to satisfy contractual obligations to the investors.